Does the tamoxifen increases thyroid dysfunction after loco-regional irradiation of breast cancer?

Koç, Mehmet; Capoglu, Ilyas; Ünüvar, Necdet

doi:10.1016/s0167-8140(01)00284-5

Cited by 2 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Previous investigators have posited that chemotherapy and hormonal therapy could have additional modifying effects. 18,19,22 We did not find evidence of a synergistic effect between radiation therapy and chemotherapy in our cohort of breast cancer patients. However, our exploratory subgroup analyses did suggest that patients with ER-positive disease (who were more likely to be treated with tamoxifen) were at higher risk than those with ER-negative and PR-negative disease.…”

Section: Discussioncontrasting

confidence: 62%

Risk of hypothyroidism in older breast cancer patients treated with radiation

Smith

Giordano

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND. Hypothyroidism is a potential complication after radiation therapy (RT) when treatment fields include the thyroid. The authors assessed risk of hypothyroidism in breast cancer patients who were receiving RT to a supraclavicular field, which typically includes a portion of thyroid. METHODS. The authors identified 38,255 women (aged >65) without history of hypothyroidism from the Surveillance, Epidemiology, and End Results (SEER)‐Medicare cohort diagnosed with stage 0‐III breast cancer from 1992–2002 and 111,944 cancer‐free controls. The authors compared hypothyroidism incidence among irradiated patients with 4 + positive lymph nodes (4 + LN, surrogate for supraclavicular RT) and no positive nodes (0 LN, surrogate for no supraclavicular RT), nonirradiated patients, and controls. Proportional hazards models tested associations of LN, RT, and breast cancer status with hypothyroidism. RESULTS. The 5‐year incidence of hypothyroidism was identical (14%) in irradiated patients with 4 + LN, 0 LN, and nonirradiated patients (P = .52). After adjusting for sociodemographic and clinical characteristics, hypothyroidism risk was not increased in irradiated patients with 4 + LN versus 0 LN (hazard ratio(HR) = 1.04; 95% confidence interval (CI), 0.89–1.23). However, all patients, regardless of RT status, were more likely to be diagnosed with hypothyroidism compared with cancer‐free controls (HR = 1.21; 95% CI, 1.17–1.25). CONCLUSIONS. Development of hypothyroidism is fairly common in older breast cancer survivors. Although supraclavicular irradiation does not appear to amplify risks, further studies on the role of routine thyroid function monitoring in all breast cancer patients regardless of treatment status may be warranted, given the excess risks compared with the general population. Cancer 2008. ©2008 American Cancer Society.

show abstract

Section: Discussioncontrasting

confidence: 62%

Risk of hypothyroidism in older breast cancer patients treated with radiation

Smith

Giordano

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…The reason for the high prevalence of clinical hypothyroidism in BC patients seems to also be multifactorial. It is postulated that malignancy per se could be a predisposing condition for hypothyroidism (13)(14)(15)(25)(26)(27). The occurrence of hypothyroidism in cancer is attributed to various cytokines secreted by the tumor that inhibit the function of the hypothalamuspituitary-thyroid axis and peripheral conversion of T 4 to T3.…”

Section: Discussionmentioning

confidence: 99%

“…One suggested that thyroid dysfunction is not related to an increased risk of BC, whereas the other, which analyzed the effect of thyroid dysfunction on site-specific cancer risk, concluded that thyroid dysfunction was associated with an increased risk of BC ( 11 , 12 ). Whether hypothyroidism is a risk factor for the development of BC or a sequelae of multimodal cancer therapy is also not clear ( 7 , 13 – 15 ). The reported prevalence of thyroid dysfunction and autoimmunity in BC ranges from 9.3% to 56%.…”

Section: Introductionmentioning

confidence: 99%

Thyroid dysfunctions and autoimmunity in breast cancer patients: a prospective case-control study

Jha

Mishra

Yadav

et al. 2020

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Objective: The relationship of thyroid dysfunction and autoimmunity with breast cancer (BC) continues to be contentious. The primary aim of this study was to estimate the prevalence of thyroid dysfunctions and autoimmunity in BC patients, and the secondary aims were to investigate the relationship of thyroid dysfunction with the clinicopathological profile of and therapy received by BC patients. Materials and methods: This was a single-center prospective case-control study (March 2015-May 2017). Women with BC (n = 191), age-matched healthy controls (n = 166) and malignant controls (patients with cervical cancer, n = 87) were enrolled. Basal serum free thyroxin (fT4), thyrotropin (TSH) and anti-thyroid peroxidase (TPO) antibody levels were measured in all three groups; fT4, TSH and TPO measures were repeated after chemotherapy and at the 1-year follow-up (one year after diagnosis) in the BC patients. Results: The prevalence of overall hypothyroidism and autoimmunity (p = 0.106) did not differ significantly between the three groups, but the rate of clinical hypothyroidism was significantly higher in the BC group than in the healthy control group and the malignant control group (12.2% vs. 3.0% vs. 4.6%, respectively; p = 0.001). BC patients had significantly lower mean basal TSH concentrations than the healthy controls (p = 0.017). The postchemotherapy TSH concentrations were significantly lower (p = 0.001), and the fT4 concentrations were higher, albeit not significantly (p = 1.00), than the respective basal concentrations. The reverse was true for the follow-up values, in which the TSH (p = 1.00) values were higher and the fT4 (p = 0.03) concentrations were lower than the respective basal concentrations. An additional 6% of the BC patients developed clinical hypothyroidism during follow-up. Hypothyroid (p = 0.02) and TPO-positive (p = 0.004) patients had significantly smaller tumors, but their other clinicopathological features were comparable to those without thyroid dysfunction. Conclusions: The prevalence of clinical hypothyroidism requiring thyroxine replacement was significantly high in BC patients and increased further during follow-up. Hence, BC patients should be considered a high-risk group that should receive routine screening for hypothyroidism.

show abstract

Does the tamoxifen increases thyroid dysfunction after loco-regional irradiation of breast cancer?

Cited by 2 publications

References 8 publications

Risk of hypothyroidism in older breast cancer patients treated with radiation

Risk of hypothyroidism in older breast cancer patients treated with radiation

Thyroid dysfunctions and autoimmunity in breast cancer patients: a prospective case-control study

Contact Info

Product

Resources

About